Figure 6.

PeptiCRAd elicited local and systemic antitumor response in a poor immunogenic tumor melanoma model. (A) Immunocompetent C57Bl/6 mice were subcutaneously injected with the syngeneic tumor model B16.F1 in the left (0.5x10⁴ cells) and right flank (1x10⁵). Ad5/3Δ24, AdEpitopes and PeptiCRAd were intratumorally administrated four times, two days apart starting from day 9. The B16F1 tumor growth was followed until the end of the experiment and the tumor size is presented as the mean ± SEM and statistically difference was assessed with two-way ANOVA; (ns P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001). (B–E) Single tumor growth for single mouse for Mock (B), Ad5/3Δ24 (C), AdEpitopes (D) and PeptiCRAd (E) is shown. A threshold of 431 mm³ was set to define the percentage of mice responding to the different therapies (red dotted line) for right and left tumors. The percentage of responders in each treatment group is shown on the top of the dotted line. The threshold was defined as the median of the tumor size at the last day of the experiment in Ad5/3Δ24 treated group. (Mock n=9, Ad5/3 Δ24n=9, AdEpitopes n= 9, PeptiCRAd n=8).